CervoMed Inc./$CRVO
1D1W1MYTD1Y5YMAX
About CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
- Ticker
- $CRVO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- Boston, United States
- Website
- www.cervomed.com
CervoMed Inc. Metrics
BasicAdvanced
$39M
-
-$3.19
-4.31
-
Price and volume
Market cap
$39M
Beta
-4.31
52-week high
$10.89
52-week low
$2.13
Average daily volume
336K
Financial strength
Current ratio
8.572
Quick ratio
8.225
Profitability
Gross margin (TTM)
-6,491.13%
Net profit margin (TTM)
-9,160.94%
Operating margin (TTM)
-9,406.82%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-60.80%
Return on equity (TTM)
-107.62%
Valuation
Price to revenue (TTM)
74.597
Price to book
1.53
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-0.883
Free cash flow yield (TTM)
-113.21%
Free cash flow per share (TTM)
-2.943
Growth
Revenue change (TTM)
-95.74%
Earnings per share change (TTM)
23.82%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.